Health Care [ 9/12 ] | Biotechnology [ 47/73 ]
NASDAQ | Common Stock
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics called antibody oligonucleotide conjugates (AOCs).
Its AOC platform is designed to combine the specificity of monoclonal antibodies with the precision of RNA therapeutics to target the root cause of diseases previously untreatable with such therapeutics.
The company's pipeline has three programs in registrational clinical trials, such as Delpacibart etedesiran, which is in Phase 3 development stage for the treatment of people with myotonic dystrophy type 1; Delpacibart braxlosiran that is in Phase 1/2 development stage for treating facioscapulohumeral muscular dystrophy; and Delpacibart zotadirsen, which is in the Phase 2 EXPLORE44 open-label extension study for the treatment of Duchenne muscular dystrophy.
The company is also developing precision cardiology candidates targeting rare genetic cardiomyopathies, including AOC 1086 for phospholamban cardiomyopathy and AOC 1072 for protein kinase AMP-activated non-catalytic subunit gamma 2 syndrome.
Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 7, 25 | -0.90 Decreased by -13.92% | -0.88 Decreased by -2.24% |
| Feb 26, 25 | -0.80 Decreased by -1.27% | -0.78 Decreased by -2.45% |
| Nov 6, 24 | -0.65 Increased by +8.45% | -0.71 Increased by +8.45% |
| Aug 9, 24 | -0.65 Increased by +1.52% | -0.79 Increased by +17.72% |
| May 9, 24 | -0.79 Decreased by -6.76% | -0.78 Decreased by -1.28% |
| Feb 28, 24 | -0.79 Increased by +10.23% | -0.66 Decreased by -19.70% |
| Nov 8, 23 | -0.71 Increased by +13.41% | -0.77 Increased by +7.79% |
| Aug 8, 23 | -0.66 Increased by +28.26% | -0.80 Increased by +17.50% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 1.57 M Decreased by -55.60% | -115.77 M Decreased by -68.14% | Decreased by -7.36 K% Decreased by -278.72% |
| Dec 31, 24 | 2.97 M Increased by +35.57% | -102.26 M Decreased by -69.18% | Decreased by -3.44 K% Decreased by -24.79% |
| Sep 30, 24 | 2.34 M Decreased by -17.10% | -80.40 M Decreased by -53.55% | Decreased by -3.44 K% Decreased by -85.24% |
| Jun 30, 24 | 2.04 M Decreased by -11.70% | -70.79 M Decreased by -50.54% | Decreased by -3.46 K% Decreased by -70.49% |
| Mar 31, 24 | 3.54 M Increased by +58.67% | -68.86 M Decreased by -45.90% | Decreased by -1.94 K% Increased by +8.04% |
| Dec 31, 23 | 2.19 M Decreased by -20.80% | -60.44 M Decreased by -26.67% | Decreased by -2.76 K% Decreased by -59.94% |
| Sep 30, 23 | 2.82 M Increased by +13.54% | -52.36 M Decreased by -23.87% | Decreased by -1.86 K% Decreased by -9.10% |
| Jun 30, 23 | 2.32 M Increased by +6.34% | -47.02 M Decreased by -2.92% | Decreased by -2.03 K% Increased by +3.21% |